BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 12435109)

  • 1. Overcoming multidrug resistance in taxane chemotherapy.
    Geney R; Ungureanu lM; Li D; Ojima I
    Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal chemistry and chemical biology of new generation taxane antitumor agents.
    Ojima I; Geney R; Ungureanu IM; Li D
    IUBMB Life; 2002; 53(4-5):269-74. PubMed ID: 12121008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the new generation taxane anticancer agents.
    Geney R; Chen J; Ojima I
    Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemistry and chemical biology of taxane anticancer agents.
    Miller ML; Ojima I
    Chem Rec; 2001; 1(3):195-211. PubMed ID: 11895119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127.
    Ferlini C; Distefano M; Pierelli L; Bonanno G; Riva A; Bombardelli E; Ojima I; Mancuso S; Scambia G
    Oncol Res; 1999; 11(10):471-8. PubMed ID: 10850888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
    Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
    J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
    Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
    Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Brooks TA; Minderman H; O'Loughlin KL; Pera P; Ojima I; Baer MR; Bernacki RJ
    Mol Cancer Ther; 2003 Nov; 2(11):1195-205. PubMed ID: 14617793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDN5109, a taxane with oral bioavailability and potent antitumor activity.
    Nicoletti MI; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati MB; Bombardelli E; D'Incalci M; Giavazzi R
    Cancer Res; 2000 Feb; 60(4):842-6. PubMed ID: 10706091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
    Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
    Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New taxanes and epothilone derivatives in clinical trials].
    Lavelle F
    Bull Cancer; 2002 Apr; 89(4):343-50. PubMed ID: 12016034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
    Sharma A; Straubinger RM; Ojima I; Bernacki RJ
    J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of taxane resistance in a panel of human lung cancer cell lines.
    Breen L; Murphy L; Keenan J; Clynes M
    Toxicol In Vitro; 2008 Aug; 22(5):1234-41. PubMed ID: 18514476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Search for new MDR modifier possessing taxane skeleton].
    Kobayashi J
    Nihon Rinsho; 1997 May; 55(5):1135-42. PubMed ID: 9155165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
    Ehrlichova M; Vaclavikova R; Ojima I; Pepe A; Kuznetsova LV; Chen J; Truksa J; Kovar J; Gut I
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):95-105. PubMed ID: 16059735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
    Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
    Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.